⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 14, 2004New England Journal of Medicine

Antiplatelet Therapy for Ischemic Heart Disease

View Full Paper

Ask AI

Bookmark

Share

Structured PICO

P

Population

Patients with ischemic heart disease, including those with acute coronary syndrome or undergoing percutaneous coronary intervention

I

Intervention

Antiplatelet therapy

This review discusses the pathophysiological role of platelet aggregation and the rationale for antiplatelet therapy in ischemic heart disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Affirms rationale for antiplatelet therapy in IHD; leaves open optimal integration with emerging agents.

Cite This Study

Lange et al. (2004) studied this question.

synapsesocial.com/papers/6a883fa5b0d802598bf4e3ca https://doi.org/10.1056/nejme038191

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial InfarctionRCT · 1998 · 1,330 citations
2Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment ElevationOriginal Research · 2001 · 6,519 citations
3Acute Antithrombotic Effect of a Front-Loaded Regimen of Clopidogrel in Patients With Atherosclerosis on Aspirincohort · 2000 · 87 citations
4A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with ClopidogrelRCT · 2004 · 570 citations
5Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesRCT · 1998 · 1,444 citations